Table 2. Risk factors for 90-day all-cause mortality among patients with blastomycosis, Quebec, Canada*.

Risk factor	Survived, n = 155		Died, n = 30	Crude odds ratio (95% CI)		p value		Adjusted odds ratio (95% CI)		p value
Study period
1988–1997	31 (94)		2 (6)	1
1998–2007	47 (82)		10 (18)	3.3 (0.7–16.1)		0.1		2.7 (0.5–15.3)		0.3
2008–2017	77 (81)		18 (19)	3.6 (0.8–16.6)		0.1		1.2 (0.2–6.5)		0.8
Median no. days of symptoms before diagnosis (IQR)	71 (26–141)		37 (18–45)	0.99 (0.99–1.00)		0.04		0.99 (0.99–1.00)		0.07
Median age, y (IQR)	54 (44–64)		62 (53–71)	1.04 (1.01–1.07)		0.004		1.04 (1.00–1.07)		0.04
Sex
F	34 (81)		8 (19)
M	121 (85)		22 (15)	0.8 (0.3–1.9)		0.6
Charlson Comorbidity Index score
0	76 (94)		5 (6)
1–2	43 (81)		10 (19)	3.5 (1.1–16.1)		0.03
≥3	36 (71)		15 (29)	6.3 (2.1–18.8)		0.001
Underlying condition
Diabetes	23 (72)		9 (28)	2.5 (1.00–6.04)		0.05
COPD	27 (79)		7 (21)	1.4 (0.6–3.7)		0.5
Immunosuppression	27 (61)		17(39)	6.2 (2.7–14.3)		<0.001		4.2 (1.5–11.6)		0.005
No. organs involved
1–2	105 (87)		16 (13)
>2	50 (78)		14 (22)	1.8 (0.8–4.1)		0.1
Radiologic manifestations
No. lobes
0–2	112 (93)		8 (7)
>2	43 (66)		22 (34)	7.2 (3.0–17.3)		<0.001		5.3 (1.9–14.3)		0.001
Miliary presentation	6 (67)		3 (33)	2.8 (0.7–11.7)		0.2
First antifungal received
Amphotericin, lipid formulations	20 (80)		5 (20)	1
Amphotericin B, deoxycholate	13 (76)		4 (24)	1.2 (0.3–5.5)		0.08
Azole	107 (96)		4 (4)	0.1 (0.04–0.61)		0.008
No treatment	15 (47)		17 (53)	4.5 (1.4–15.1)		0.01

*Values are no. (%) except as indicated. COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.